A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

CompletedOBSERVATIONAL

Enrollment

157

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

May 2, 2022

Study Completion Date

May 2, 2022

Conditions

HR+/HER2- Advanced or Metastatic Breast Cancer

Trial Locations (1)

Novartis Pharmaceuticals, Dublin